PLYMOUTH MEETING, Pa., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that Harmony's management team will participate in the following upcoming investor conferences.
Harmony Biosciences' Q3 earnings missed estimates as higher costs weighed on profits, while Wakix demand and pipeline progress supported its 2026 revenue outlook.
Harmony Biosciences NASDAQ: HRMY reported third-quarter net revenue of $269 million, up from $239 million a year earlier, as demand for its narcolepsy treatment WAKIX continued to grow. The company reiterated its full-year WAKIX net revenue guidance of $1 billion to $1.04 billion and said it expects to exceed $1 billion in annual WAKIX revenue for the first time.
Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.81 per share, missing the Zacks Consensus Estimate of $1 per share. This compares to earnings of $0.87 per share a year ago.
WAKIX ® Net Revenue in Q3 of $269 Million; Driven by Strong Demand with 400 Net Patient Adds in the Quarter; Reiterates Full Year Guidance of $1.0B to $1.04B
Harmony Biosciences (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.